Cargando…

Combination of disease duration‐to‐age at diagnosis and hemoglobin A1c‐to‐serum C‐peptide reactivity ratios predicts patient response to glucose‐lowering medication in type 2 diabetes: A retrospective cohort study across Japan (JDDM59)

AIMS/INTRODUCTION: Knowing the collective clinical factors that determine patient response to glucose‐lowering medication would be beneficial in the treatment of type 2 diabetes. We carried out a retrospective cohort study to explore the combination of clinical factors involved in its therapeutic ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanatsuka, Azuma, Sato, Yasunori, Higashi, Yoichiro, Goto, Yoshimasa, Kawai, Koichi, Maegawa, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8565405/
https://www.ncbi.nlm.nih.gov/pubmed/33837666
http://dx.doi.org/10.1111/jdi.13558
_version_ 1784593819951431680
author Kanatsuka, Azuma
Sato, Yasunori
Higashi, Yoichiro
Goto, Yoshimasa
Kawai, Koichi
Maegawa, Hiroshi
author_facet Kanatsuka, Azuma
Sato, Yasunori
Higashi, Yoichiro
Goto, Yoshimasa
Kawai, Koichi
Maegawa, Hiroshi
author_sort Kanatsuka, Azuma
collection PubMed
description AIMS/INTRODUCTION: Knowing the collective clinical factors that determine patient response to glucose‐lowering medication would be beneficial in the treatment of type 2 diabetes. We carried out a retrospective cohort study to explore the combination of clinical factors involved in its therapeutic efficacy. MATERIALS AND METHODS: The results of cohort studies retrieved using the CoDiC(®) database across Japan from January 2005 to July 2018 were analyzed based on criterion that using insulin therapy indicates severe type 2 diabetes. RESULTS: A logistic regression analysis showed that age at diagnosis, disease duration, hemoglobin A1c (HbA1c) and serum C‐peptide reactivity (CPR) at medication commencement were associated with the probability of insulin treatment. Receiver operating characteristic curve showed that these clinical factors predicted insulin treatment positivity with an area under the curve of >0.600. The area under the curve increased to 0.674 and 0.720 for the disease duration‐to‐age at diagnosis ratio and HbA1c‐to‐CPR ratio, respectively. Furthermore, area under the curve increased to 0.727 and 0.750 in the indices (duration‐to‐age ratio at diagnosis × 43 + HbA1c) and (duration‐to‐age ration at diagnosis × 21 + HbA1c‐to‐CPR ratio), respectively. After stratification to three groups according to the indices, monthly HbA1c levels during 6 months of treatment were higher in the upper one‐third than in the lower one‐third of patients, and many patients did not achieve the target HbA1c level (53 mmol/mol) in the upper one‐third, although greater than fourfold more patients were administered insulin in the upper one‐third. CONCLUSIONS: The combination of disease duration‐to‐age at diagnosis and HbA1c‐to‐CPR ratios is a collective risk factor that predicts response to the medications.
format Online
Article
Text
id pubmed-8565405
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-85654052021-11-09 Combination of disease duration‐to‐age at diagnosis and hemoglobin A1c‐to‐serum C‐peptide reactivity ratios predicts patient response to glucose‐lowering medication in type 2 diabetes: A retrospective cohort study across Japan (JDDM59) Kanatsuka, Azuma Sato, Yasunori Higashi, Yoichiro Goto, Yoshimasa Kawai, Koichi Maegawa, Hiroshi J Diabetes Investig Articles AIMS/INTRODUCTION: Knowing the collective clinical factors that determine patient response to glucose‐lowering medication would be beneficial in the treatment of type 2 diabetes. We carried out a retrospective cohort study to explore the combination of clinical factors involved in its therapeutic efficacy. MATERIALS AND METHODS: The results of cohort studies retrieved using the CoDiC(®) database across Japan from January 2005 to July 2018 were analyzed based on criterion that using insulin therapy indicates severe type 2 diabetes. RESULTS: A logistic regression analysis showed that age at diagnosis, disease duration, hemoglobin A1c (HbA1c) and serum C‐peptide reactivity (CPR) at medication commencement were associated with the probability of insulin treatment. Receiver operating characteristic curve showed that these clinical factors predicted insulin treatment positivity with an area under the curve of >0.600. The area under the curve increased to 0.674 and 0.720 for the disease duration‐to‐age at diagnosis ratio and HbA1c‐to‐CPR ratio, respectively. Furthermore, area under the curve increased to 0.727 and 0.750 in the indices (duration‐to‐age ratio at diagnosis × 43 + HbA1c) and (duration‐to‐age ration at diagnosis × 21 + HbA1c‐to‐CPR ratio), respectively. After stratification to three groups according to the indices, monthly HbA1c levels during 6 months of treatment were higher in the upper one‐third than in the lower one‐third of patients, and many patients did not achieve the target HbA1c level (53 mmol/mol) in the upper one‐third, although greater than fourfold more patients were administered insulin in the upper one‐third. CONCLUSIONS: The combination of disease duration‐to‐age at diagnosis and HbA1c‐to‐CPR ratios is a collective risk factor that predicts response to the medications. John Wiley and Sons Inc. 2021-05-12 2021-11 /pmc/articles/PMC8565405/ /pubmed/33837666 http://dx.doi.org/10.1111/jdi.13558 Text en © 2021 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Articles
Kanatsuka, Azuma
Sato, Yasunori
Higashi, Yoichiro
Goto, Yoshimasa
Kawai, Koichi
Maegawa, Hiroshi
Combination of disease duration‐to‐age at diagnosis and hemoglobin A1c‐to‐serum C‐peptide reactivity ratios predicts patient response to glucose‐lowering medication in type 2 diabetes: A retrospective cohort study across Japan (JDDM59)
title Combination of disease duration‐to‐age at diagnosis and hemoglobin A1c‐to‐serum C‐peptide reactivity ratios predicts patient response to glucose‐lowering medication in type 2 diabetes: A retrospective cohort study across Japan (JDDM59)
title_full Combination of disease duration‐to‐age at diagnosis and hemoglobin A1c‐to‐serum C‐peptide reactivity ratios predicts patient response to glucose‐lowering medication in type 2 diabetes: A retrospective cohort study across Japan (JDDM59)
title_fullStr Combination of disease duration‐to‐age at diagnosis and hemoglobin A1c‐to‐serum C‐peptide reactivity ratios predicts patient response to glucose‐lowering medication in type 2 diabetes: A retrospective cohort study across Japan (JDDM59)
title_full_unstemmed Combination of disease duration‐to‐age at diagnosis and hemoglobin A1c‐to‐serum C‐peptide reactivity ratios predicts patient response to glucose‐lowering medication in type 2 diabetes: A retrospective cohort study across Japan (JDDM59)
title_short Combination of disease duration‐to‐age at diagnosis and hemoglobin A1c‐to‐serum C‐peptide reactivity ratios predicts patient response to glucose‐lowering medication in type 2 diabetes: A retrospective cohort study across Japan (JDDM59)
title_sort combination of disease duration‐to‐age at diagnosis and hemoglobin a1c‐to‐serum c‐peptide reactivity ratios predicts patient response to glucose‐lowering medication in type 2 diabetes: a retrospective cohort study across japan (jddm59)
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8565405/
https://www.ncbi.nlm.nih.gov/pubmed/33837666
http://dx.doi.org/10.1111/jdi.13558
work_keys_str_mv AT kanatsukaazuma combinationofdiseasedurationtoageatdiagnosisandhemoglobina1ctoserumcpeptidereactivityratiospredictspatientresponsetoglucoseloweringmedicationintype2diabetesaretrospectivecohortstudyacrossjapanjddm59
AT satoyasunori combinationofdiseasedurationtoageatdiagnosisandhemoglobina1ctoserumcpeptidereactivityratiospredictspatientresponsetoglucoseloweringmedicationintype2diabetesaretrospectivecohortstudyacrossjapanjddm59
AT higashiyoichiro combinationofdiseasedurationtoageatdiagnosisandhemoglobina1ctoserumcpeptidereactivityratiospredictspatientresponsetoglucoseloweringmedicationintype2diabetesaretrospectivecohortstudyacrossjapanjddm59
AT gotoyoshimasa combinationofdiseasedurationtoageatdiagnosisandhemoglobina1ctoserumcpeptidereactivityratiospredictspatientresponsetoglucoseloweringmedicationintype2diabetesaretrospectivecohortstudyacrossjapanjddm59
AT kawaikoichi combinationofdiseasedurationtoageatdiagnosisandhemoglobina1ctoserumcpeptidereactivityratiospredictspatientresponsetoglucoseloweringmedicationintype2diabetesaretrospectivecohortstudyacrossjapanjddm59
AT maegawahiroshi combinationofdiseasedurationtoageatdiagnosisandhemoglobina1ctoserumcpeptidereactivityratiospredictspatientresponsetoglucoseloweringmedicationintype2diabetesaretrospectivecohortstudyacrossjapanjddm59
AT combinationofdiseasedurationtoageatdiagnosisandhemoglobina1ctoserumcpeptidereactivityratiospredictspatientresponsetoglucoseloweringmedicationintype2diabetesaretrospectivecohortstudyacrossjapanjddm59